News
MD Anderson and Sibylla Biotech announce strategic...
Belfer family’s $20 million donation invigorates...
Advances in cancer neuroscience and drug discovery could...
MD Anderson and CureVac enter strategic collaboration to...
More News
News Releases
MD Anderson Research Highlights for February 1, 2023
Androgen receptor signaling contributes to targeted therapy resistance in melanoma
Research Highlights for June 1, 2022
Novel therapy could help people with asthma, COPD, cystic fibrosis and cancer-related lung disease
Research Highlights for March 9, 2022
Research Highlights for February 9, 2022
Research Highlights SITC 2021 Special Edition
Research Highlights for October 20, 2021
Research Highlights for September 22, 2021
Research Highlights for August 25, 2021
MD Anderson and Broad Institute launch new translational research platform focused on rare cancers
MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021
$24 million in CPRIT funding awarded to MD Anderson and related research
Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy
Giulio Draetta named Chief Scientific Officer
New therapeutic target found for aggressive pediatric cancers with few treatment options
MD Anderson and Ipsen announce joint bench-to-bedside cancer drug development partnership
MD Anderson Publications
Cancerwise
- TIL therapy: 6 things to know
- How Therapeutics Discovery is developing targeted therapies for more cancer types
- Monoclonal antibodies and cancer treatment: What to know
Cancer Frontline
- MD Anderson accelerates cellular therapy programs by buying state-of-art manufacturing facility
- TRACTION accelerates translation of discoveries into new clinical approaches
- AML drug may be good for KRAS-driven pancreatic cancer, computer-aided drug discovery finds
- MD Anderson advances novel therapeutic antibody into AML clinical trials